Merck Expands Aduro Collaboration In Keytruda Tie-Up
Aduro Biotech's scientists have a long association with Merck & Co's Keytruda, and things have come full circle as the small biotech's lead anticancer shows promise in combination with the high-profile checkpoint inhibitor.
You may also be interested in...
Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.